Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group

Brock C, Olesen SS, Olesen AE, Frakjsr JF, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012;72:1847-65, http://dx.doi.org/10.2165/11634970-000000000-0000010.2165/11634970-000000000-0000022950533 Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11S-8S, pii:S0002961001007826. Holzer P. Pharmacology of opioids and their effects on gastrointestinal function. Am J Gastroenterol Suppl 2014;2:9-16.10.1038/ajgsup.2014.4 Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649-71.10.2165/00003495-200363070-0000312656645 Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004;16:3-16.10.1111/j.1743-3150.2004.00553.x15357847 Camilleri M, Malagelada JR, Stangilellini V, Zinsmeister AR, Kao PC, Li CH. Dose-related effects of synthetic human and naloxone on fed gastrointestinal motility. AmJ Physiol 1986;251:G147-54.2942039 Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol 2014;2:17-21, http://dx.doi.org/10.1038/ajgsup.2014.510.1038/ajgsup.2014.5 Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Bell D. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7.10.5414/CP20164622541841 SharmaSK, NirenbergM, Klee WA. Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci USA 1975;72:590-4.10.1073/pnas.72.2.590 Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004;16:17-28.10.1111/j.1743-3150.2004.00554.x15357848 Gonenne J, Camilleri M, Ferber I, Burton D, Baxter K, Keyashian K, Foss J, Wallin B, Du W, Zinsmeister AR. Effect of alvimopan and codeine ongastroeintestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005;3:784-91.1623400710.1016/S1542-3565(05)00434-9 Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther 2010;31:601-6, http://dx.doi.org/10.1111/j.1365-2036.2009.04212.x10.1111/j.1365-2036.2009.04212.x20003176 Penagini R, Allocca M, Cantu P, Mangano M, Savojardo D, Carmagnola S, Bianchi PA. Relationship between motor function of the proximal stomach and transient lower oesophageal sphincter relaxation after morphine. Gut 2004;53:1227-31.10.1136/gut.2003.03524615306575 Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Naloxone treatment for irritable bowel syndrome—a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002;16:1649-54.10.1046/j.1365-2036.2002.01320.x12197844 Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Palaniappan K, Church A, Limb M, Connor A. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011;20:427-39, http://dx.doi.org/10.1517/13543784.2011.5632362139548310.1517/13543784.2011.563236 Sun WM, Read NW, Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol 1997;32:34-8.10.3109/003655297090250609018764 Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 2007;16:181-94.1724393810.1517/13543784.16.2.181 Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage 2008;35:103-13.1798100310.1016/j.jpainsymman.2007.01.017 Barrett KE, KeelySJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 2000;62:535-72.10.1146/annurev.physiol.62.1.53510845102 Glad H, Ainsworth MA, Svendsen P, Fahrenkrug J, Schaffalitzky de Muckadell OB. Effect of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on pancreatic, hepatic and duodenal mucosal bicarbonate secretion in the pig. Digestion 2003;67:56-66.1274344210.1159/000069707 KromerW. Endogenous and exogenous opioids inthe control of gastrointestinal motility and secretion. Pharmacol Rev 1988;40:121-62. Dowlatshahi K, EvanderA, Walther B, Skinner DB. Influence of morphine on the distal oesophagus and the lower oesophageal sphincter—a manometric study. Gut 1985;26:802-6.10.1136/gut.26.8.8024018646 Blackshaw LA, Bordin DS, Brock C, Brokjaer A, Drewes AM, Farmer AD, Krarup AL, Lottrup C, Masharova AA, Moawad FJ, Olesen AE. Pharmacologic treatments for esophageal disorders. Ann N Y Acad Sci 2014;1325:23-39, http://dx.doi.org/10.1111/nyas.1252010.1111/nyas.1252025266012 Sharma SS. Sphincter of Oddi dysfunction in patients addicted to opium: an unrecognized entity. Gastrointest Endosc 2002;55:427-30.10.1067/mge.2002.12160011868024 Bouvier M, KirschnerG, GonellaJ. Actions of morphine and enkephalins on the internal anal sphincter of the cat: relevance for the physiological role of opiates.J Auton Nerv Syst 1986;16:219-32.10.1016/0165-1838(86)90028-7 Burleigh DE, D’Mello A. Neural and pharmacologic factors affecting motility of the internal anal sphincter. Gastroenterology 1983;84:409-17.6336709 Gaertner J, Siemens W, Camilleri M, Davies A, Drossman DA, Webster LR, Becker G. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol 2015;49:9-16, http://dx.doi.org/10.1097/MCG.000000000000024610.1097/MCG.000000000000024625356996 Longstreth GF, Thompson WG, CheyWD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.1667856110.1053/j.gastro.2005.11.061 Choung RS, Locke 3rd GR, Schleck CD, Zinsmeister AR, Talley NJ. Cumulative incidence of chronic constipation: a population-based study 1988-2003. Aliment Pharmacol Ther 2007;26:1521-8.1791927110.1111/j.1365-2036.2007.03540.x Clark K, Currow DC. Constipation in palliative care: what do we use as definitions and outcome measures? J Pain Symptom Manage 2013;45:753-62, http://dx.doi.org/10.1016/jjpainsymman.2012.03.0162294055910.1016/j.jpainsymman.2012.03.016 Bharucha AE, Pemberton JH, Locke 3rd GR. American Gastroenterological Association technical review on constipation. Gastroenterology 2013;144:218-38, http://dx.doi.org/10.1053Zj.gastro.2012.10.02810.1053/j.gastro.2012.10.02823261065 Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil 2014;26:1386-95, http://dx.doi.org/10.1111/nmo.1241710.1111/nmo.12417 Gaertner J, Siemens W, Camilleri M, Davies A, Drossman DA, Webster LR, Becker G. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroentero 2015;49:9-16, http://dx.doi.org/10.1097/MCG10.1097/MCG.0000000000000246 Drossman D, Szigethy E. The narcotic bowel syndrome: a recent update. Am J Gastroenterol 2014;2:22-30, http://dx.doi.org/10.1038/ajgsup.2014610.1038/ajgsup.2014.6 Kurlander JE, Drossman DA. Diagnosis and treatment of narcotic bowel syndrome. Nat RevGastroenterol Hepatol 2014;11:410-8, http://dx.doi.org/10.1038/nrgastro.20145310.1038/nrgastro.2014.53 Institute for Healthcare Informatics IMS. The use of medicines in the United States: review of2010. Parsippany, NJ;2011. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced boweldysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35-42, http://dx.doi.org/10.1111/j.1526-4637.2008.00495.x10.1111/j.1526-4637.2008.00495.x Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther2008;27:1224-32, http://dx.doi.org/10.1111/j.1365-2036.2008.03689.x10.1111/j.1365-2036.2008.03689.x18363893 Holzer P. New approaches to the treatment of opioid-induced constipation. EurRev Med Pharmacol Sci 2008;12:119-27.18924451 Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80.1556139310.1016/j.pain.2004.09.019 Sykes NP.The relationship between opioid use and laxative use interminally ill cancerpatients. Palliat Med 1998;12:375-82.10.1191/026921698674125048 Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic noncancer pain. Neurogastroenterol Motil 2010;22:424-30, http://dx.doi.org/10.1111/j.1365-2982.2009.01458.x10.1111/j.1365-2982.2009.01458.x Hjalte F, Berggren A-C, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010;40:696-703, http://dx.doi.org/10.1016/j.jpainsymman.2010.02.0192072770810.1016/j.jpainsymman.2010.02.019 Gekas P, Schuster MM. Sterocoral perforation of the colon: case report and review of the literature. Gastroenterology 1981;80:1054-8.7202964 Locke 3rd GR, Pemberton JH, Phillips SF. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology2000;119:1761-6.10.1053/gast.2000.2039011113098 Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep 2001;5:237-40.10.1007/s11916-001-0037-711309211 Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother 2009;23:231-41, http://dx.doi.org/10.1080/153602809030984401967002010.1080/15360280903098440 Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005;23:461-76.10.2165/00019053-200523050-00006 Morlion B, Clemens KE, Dunlop W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. Clin Drug Investig 2015;35:1-11, http://dx.doi.org/10.1007/s40261-014-0254-62547995910.1007/s40261-014-0254-6 Coffin B, Causse C. Constipation assessment scales in adults: a literature review including the new Bowel Function Index. Expert Rev Gastroenterol Hepatol 2011;5:601-13, http://dx.doi.org/10.1586/egh.11.532191057810.1586/egh.11.53 Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum 1996;39:681-5.10.1007/BF020569508646957 McMillan SC, Williams FA. Validity and reliability of the Constipation Assessment Scale. Cancer Nurs 1989;12:183-8.10.1097/00002820-198906000-000122743302 Knowles CH, Eccersley AJ, Scott SM, Walker SM, Reeves B, Lunniss PJ. Linear discriminant analysis of symptoms in patients with chronic constipation: validation of a new scoring system (KESS). Dis Colon Rectum 2000;43:1419-26.10.1007/BF0223663911052520 Griffenberg L, Morris M, Atkinson N, Levenback C. The effect of dietary fibre on bowel function following radical hysterectomy: a randomized trial. Gynecol Oncol 1997;66:417-24.10.1006/gyno.1997.47979299255 Frank L, FlynnJ, Rothman M. Use of a self-report constipation questionnaire with olderadults in long-term care. Gerontologist 2001;41:778-86.10.1093/geront/41.6.778 PamukON, PamukGE, CelikAF. Revalidation of description of constipation in terms of recall bias and visual scale analogue questionnaire. J Gastroenterol Hepatol 2003;18:1417-22.10.1046/j.1440-1746.2003.03155.x Garrigues V, Galvez C, Ortiz V, Ponce M, Nos P, Ponce J. Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a populationbased survey in Spain. AmJ Epidemiol 2004;159:520-6.10.1093/aje/kwh072 Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009;12:371-83, http://dx.doi.org/10.3111/1369699090343048110.3111/1369699090343048119912069 Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-90.10.1053/j.gastro.2006.03.00816678553 Drossman DA, Dumitrascu DL. Rome III: newstandard for functional gastro intestinal disorders. J Gastrointestin Liver Dis 2006;15:237-41. Bharucha AE, Locke 3rd GR, Seide BM, Zinsmeister AR. A new questionnaire for constipation and faecal incontinence. Aliment Pharmacol Ther 2004;20:355-64.10.1111/j.1365-2036.2004.02028.x15274673 Rentz AM, van Hanswijck de Jonge P, Leyendecker P, Hopp M. Observational, non-intervention, multicentre study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin 2011;27:35-44, http://dx.doi.org/10.1185/03007995.2010.53527010.1185/03007995.2010.535270 Ueberall MA, Muller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 2011;39:41-50.10.1177/14732300110390010621672306 Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, Webster LR. Consensus recommendations in initiating therapies for opioid-induced constipation. Pain Med 2015, http://dx.doi.org/10.1111/pme.1293726582720 Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract 2011;65:472-8, http://dx.doi.org/10.1111/j.1742-1241.2011.02634.x10.1111/j.1742-1241.2011.02634.x21401835 Mehta V, Alaward S, Kuravinakop S, Nikolic S. Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for nonmalignant pain unabletotolerate laxatives. Pain Physician 2014;17:415-24. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370:2387-96, http://dx.doi.org/10.1056/NEJMoa13102462489681810.1056/NEJMoa1310246 Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, Snidow J, Pierce A, Mortensen E, Kleoudis C, Carter E. Alvimopan, a peripherallyacting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137:428-40, http://dx.doi.org/10.1016/j.pain.200711.00818164818 Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013;154:1542-50, http://dx.doi.org/10.1016/j.pain.201304.02410.1016/j.pain.2013.04.02423726675 Kulich KR, Madisch A, Pacini F, Pique JM, Regula J, VanRensburg CJ, Ujszaszy L, Carlsson J, Halling K, Wiklund IK. Reliabilityand validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes 2008;6:12, http://dx.doi.org/10.1186/1477-7525-6-1210.1186/1477-7525-6-12 StarreveldJS, Pols MA, Van Wijk HJ, Bogaard JW, Poen H, Smout AJ. The plain abdominal radiograph in the assessment of constipation. Z Gastroenterol 1990;28:335-8.2238762 Breivik H. Local anesthetic blocks and epidurals. In: McMahon SB, Koltzenburg M, editors. Wall and Melzack’s textbook of pain. 6th ed. Philadelphia PA: Elsevier; 2013. p. 523-37. Lubawski J, Saclarides T. Postoperative ileus: strategies for reduction. Ther Clin Risk Manag 2008;4:913-7.10.2147/TCRM.S239019209273 Popping DM, Elia N, Van Aken HK, Marret E, Schug SA, Kranke P, Wenk M, Tramer MR. Impact of epidural analgesia on mortality and morbidity after surgery: systematic review and meta-analysis of randomized controlled trials. Ann Surg 2014;259:1056-67, http://dx.doi.org/10.1097/SLA.00000000000002372409676210.1097/SLA.0000000000000237 Niemi G [PhD thesis] Optimizing postoperative epidural analgesia. Faculty of Medicine, University of Oslo. Series of dissertations submitted to the Faculty of Medicine, University of Oslo, no. 219;2004, ISBN 82-8072-176-2. Stenseth R, Sellevold O, Breivik H. Epidural morphine for postoperative pain: experiencewith 1085 patients. ActaAnaesth Scand 1985;29:146-56. Bauer AJ, Boeckxstaens GE. Mechanisms of postoperative ileus. Neurogastroenterol Motil 2004;16:54-60.10.1111/j.1743-3150.2004.00558.x Vaughan-Shaw PG, FecherIC, Harris S, Knight JS. Ameta-analysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recoveryprogram after abdominal surgery. Dis Colon Rectum 2012;55:611-20, http://dx.doi.org/10.1097/DCR.0b013e318249fc7810.1097/DCR.0b013e318249fc78 Camilleri M. Opioid-induced constipation: challenges and the rapeuticopportunities. Am J Gastroenterol 2011;106:835-42, http://dx.doi.org/10.1038/ajg.2011302134391910.1038/ajg.2011.30 Malmi H, Kautiainen H, Virta LJ, Farkkila N, Koskenpato J, Farkkila MA. Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Aliment Pharmacol Ther 2014;39:496-506, http://dx.doi.org/10.1111/apt.1262010.1111/apt.1262024461085 Hatlebakk JG, Emken BE, Glazkov V, Hoff DA, Hausken T. Correct use of proton pump inhibitors for gastro-oesophageal reflux disease. Tidsskr Nor Laegeforen 2013;133:43-6, http://dx.doi.org/10.4045/tidsskr.12.001923306993 Markland AD, Palsson O, Goode PS, Burgio KL, Busby-WhiteheadJ, Whitehead WE. Association of low dietary intake of fibre and liquids with constipation: evidence from the National Health and Nutrition Examination Survey. Am J Gastroenterol 2013;108:796-803, http://dx.doi.org/10.1038/ajg.20137310.1038/ajg.2013.7323567352 Quigley EM. Probiotics in the management of functional bowel disorders: promise fulfilled? Gastroenterol Clin North Am 2012;41:805-19, http://dx.doi.org/10.1016Zj.gtc.2012.08.0052310168810.1016/j.gtc.2012.08.005 Strid H, Simren M, Storsrud S, Stotzer PO, Sadik R. Effect of heavy exercise on gastrointestinal transit in endurance athletes. Scand J Gastroenterol 2011;46:673-7, http://dx.doi.org/10.3109/00365521.2011.55811010.3109/00365521.2011.55811021366388 Wang Y, Kondo T, Suzukamo Y, Oouchida Y, Izumi S. Vagal nerve regulation is essential for the increase in gastric motility in response to mild exercise. Tohoku J Exp Med 2010;222:155-63.10.1620/tjem.222.15520948179 El-Salhy M, Svensen R, Hatlebakk JG, Gilja OH, Hausken T. Chronic constipation and treatment options. Mol Med Rep 2014;9:3-8, http://dx.doi.org/10.3892/mmr.2013.177010.3892/mmr.2013.177024189940 Twycross R, Sykes N, Mihalyo M, Wilcock A. Stimulant laxatives and opioid-induced constipation. J Pain Symptom Manage 2012;43:306-13, http://dx.doi.org/10.1016/jjpainsymman.2011.12.00210.1016/j.jpainsymman.2011.12.00222248790 Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011;60:209-18, http://dx.doi.org/10.1136/gut.2010.2271322120587910.1136/gut.2010.227132 Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002;47:2222-30.10.1023/A:102013112639712395895 Brenner DM, Chey WD. Anevidence-base dreview of novel and emerging therapies for constipation in patients taking opioid analgesics. Am J Gastroenterol Suppl 2014;2:38-46.10.1038/ajgsup.2014.8 Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Evolving paradigms in the treatment of opioid-induced bowel dysfunction. Therap Adv Gastroenterol 2015, http://dx.doi.org/10.1177/1756283X15589526 [published online before print June 15]26557892 Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage 2009;38:683-90, http://dx.doi.org/10.1016/jjpainsymman.2009.02.23410.1016/j.jpainsymman.2009.02.23419713070 Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T, Araki H, Itoh Y, Japanese Study Group for the Relief of Opioid-induced Gastrointestinal Dysfunction. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 2012;28:373-81, http://dx.doi.org/10.1097/AJP.0b013e318237d62610.1097/AJP.0b013e318237d626 Basilisco G, Marino B, Passerini L, Ogliari C. Abdominal distension after colonic lactulose fermentation recorded by a new extensometer. Neurogastroenterol Motil 2003;15:427-33.1284673110.1046/j.1365-2982.2003.00426.x Nalamachu SR. Opioid rotation inclinical practice.AdvTher2012;29:849-63, http://dx.doi.org/10.1007/s12325-012-0051-710.1007/s12325-012-0051-7 Allan L, Richarz U, Simpson K, Slappendel R.Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine (Phila Pa 1976) 2005;15:2484-90. van Seventer R, SmitJM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19:457-69.1459451610.1185/030079903125002045 Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev 2013;10, http://dx.doi.org/10.1002/14651858.CD010270.pub2.CD010270 Fine PG. Clinical approaches to special issues related to opioid therapy. Semin Oncol Nurs 2009;25:20-8, http://dx.doi.org/10.1016/j.soncn.2009.03.01110.1016/j.soncn.2009.03.011 Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004;3:CD004847. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med 2012;13:562-70, http://dx.doi.org/10.1111/j.1526-4637.2012.01357.x10.1111/j.1526-4637.2012.01357.x22458884 Kress HG. Tapentadol and itstwo mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010;14:781-3, http://dx.doi.org/10.1016/j.ejpain.2010.06.01710.1016/j.ejpain.2010.06.017 Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol 2014;2:31-7, http://dx.doi.org/10.1038/ajgsup.2014710.1038/ajgsup.2014.7 Parsons HA, de la Cruz M, El Osta B, Li Z, Calderon B, Palmer JL, Bruera E. Methadone initiation and rotation in the outpatient setting for patients with cancerpain. Cancer2010;116:520-8, http://dx.doi.org/10.1002/cncr.2475410.1002/cncr.24754 Kwong WJ, Hammond G, Upmalis D, Okamoto A, Yang M, Kavanagh S. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain. Clin J Pain 2013;29:664-72, http://dx.doi.org/10.1097/AJP.0b013e318274b69510.1097/AJP.0b013e318274b69523835764 Thakur D, Dickerson S, Kumar Bhutani M, Junor R. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients’ daily functioning in compar is on with extended-releaset a pentadol:asystematic review. ClinTher 2015;37:212-24, http://dx.doi.org/10.1016/jxlinthera.201412.00110.1016/j.clinthera.2014.12.001 Daeninck PJ, Bruera E. Reduction in constipation and laxative requirements following opioid rotation to methad one: are port off ourcases. J Pain Symptom Manage 1999;18:303-9.10.1016/S0885-3924(99)00086-X Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001;19:2898-904.10.1200/JCO.2001.19.11.289811387363 Abdulla A, Adams N, Bone M, Elliott AM, Gaffin J, Jones D, Knaggs R, Martin D, Sampson L, Schofield P. British Geriatric Society Guidance on the management of pain in older people. Age Ageing 2013;42, http://dx.doi.org/10.1093/ageing/afs200,11-57 Devin CJ, McGirt MJ. Best evidence in multimodal pain management in spine surgery and means of assessing postoperative pain and functional outcomes. J Clin Neurosci 2015;22:930-8, http://dx.doi.org/10.1016/jjocn.201501.0032576636610.1016/j.jocn.2015.01.003 Centre forClinical Practiceat NICE (UK). Neuropathicpain.The pharmacological management of neuropathic pain in adults in non-specialist settings. NICE Clinical Guidelines, No. 173; November2013; last modified December 2014. http://www.nice.org.uk/guidance/cg173/resources/guidance-neuropathic-pain-pharmacological-management-pdf[accessed 25.05.15]. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;4, http://dx.doi.org/10.1002/14651858.CD007938.pub3.CD007938 Zhang S, Paul J, Nantha-Aree M, Buckley N, Shahzad U, Cheng J, DeBeer J, Winemaker M, Wismer D, Punthakee D, Avram V, Thabane L. Reanalysis of morphine consumption from two randomized controlled trials of gabapentin using longitudinal statistical methods. J Pain Res 2015;8:79-85, http://dx.doi.org/10.2147/JPR.S5655825709496 Tornblom H, Drossman DA. Centrally targeted pharmacotherapy for chronic abdominal pain. Neurogastroenterol Motil 2015;27:455-67, http://dx.doi.org/10.1111/nmo.12509[Epub 03.02.15]10.1111/nmo.1250925651186 Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015;1, http://dx.doi.org/10.1002/14651858.CD011209.pub2.CD011209 Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev 2014;9, http://dx.doi.org/10.1002/14651858.CD011003.pub2.CD011003 Lacy BE, Levy LC. Lubiprostone: a chloride channel activator.J Clin Gastroenterol 2007;41:345-51.10.1097/01.mcg.0000225665.68920.df17413599 Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090-7, http://dx.doi.org/10.1007/s10620-009-1068-x2001248410.1007/s10620-009-1068-x Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41, http://dx.doi.org/10.1111/j.1365-2036.2008.03881.x10.1111/j.1365-2036.2008.03881.x19006537 Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014;15:1825-34, http://dx.doi.org/10.1111/pme.1243710.1111/pme.1243724716835 Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic non-cancer pain. Am J Gastroenterol 2015;110:725-32, http://dx.doi.org/10.1038/ajg.201510610.1038/ajg.2015.106 Marciniak CM, Toledo S, Lee J, Jesselson M, Bateman J, Grover B, Tierny J. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial. World J Gastroenterol 2014;20:16323-33, http://dx.doi.org/10.3748/wjg.v20.i43.1632310.3748/wjg.v20.i43.1632325473191 Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, Cohen MB, Kurtz CB, Currie MG. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010;86:760-5, http://dx.doi.org/10.1016Zj.lfs.2010.03.0152030755410.1016/j.lfs.2010.03.015 Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, Fioramonti J, Cohen M, Bryant AP, Kurtz C, Currie MG, Mayer EA, Bueno L. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-84, http://dx.doi.org/10.1111/j.1365-2982.2009.01385.x10.1111/j.1365-2982.2009.01385.x19706070 Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, Shao JZ, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Eng P, Fox SM, Johnston JM. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-36, http://dx.doi.org/10.1056/NEJMoa10108632183096710.1056/NEJMoa1010863 Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-24.10.1038/ajg.2012.25522986440 BriejerMR, Bosmans JP, Van Daele P, Jurzak M, Heylen L, Leysen JE, Prins NH, Schuurkes JA. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;29:71-83. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001;13:465-72.10.1046/j.1365-2982.2001.00280.x11696108 TackJ, Quigley E, Camilleri M, Vandeplassche L, Kerstens R. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United European. Gastroenterol J 2013;1:48-59, http://dx.doi.org/10.1177/205064061247465110.1177/205064061247465124917940 Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic non-cancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55:2912-21, http://dx.doi.org/10.1007/s10620-010-1229-y10.1007/s10620-010-1229-y Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23:48-53.1177966810.1016/S0885-3924(01)00369-4 De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383-94.1530599210.1111/j.1365-2982.2004.00513.x Smith TH, Grider JR, Dewey WL, Akbarali HI. Morphine decreases enteric neuron excitability via inhibition of sodium channels. PLoS ONE 2012;7:e45251, http://dx.doi.org/10.1371/journal.pone.00452512302888110.1371/journal.pone.0045251 Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60, http://dx.doi.org/10.1177/02692163114188692193756810.1177/0269216311418869 Lowenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43, http://dx.doi.org/10.1517/146565609027967981924330610.1517/14656560902796798 MeissnerW, Leyendecker P, Mueller-LissnerS, NadstawekJ, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K. A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. EurJ Pain 2009;13:56-64, http://dx.doi.org/10.1016/j.ejpain.2008.06.01210.1016/j.ejpain.2008.06.012 Simpson K, Leyendecker P, Hopp M, Muller-Lissner S, Lowenstein O, De Andres J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, Reimer K. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe non-cancer pain. Curr Med Res Opin 2008;24:3503-12, http://dx.doi.org/10.1185/0300799080258445410.1185/03007990802584454 Movafegh A, Shoeibi G, Ansari M, Sadeghi M, Azimaraghi O, Aghajani Y. Naloxone infusion and post-hysterectomy morphine consumption: a doubleblind, placebo-controlled study. Acta Anaesthesiol Scand 2012;56:1241-9, http://dx.doi.org/10.1111/j.1399-6576.2012.02764.x10.1111/j.1399-6576.2012.02764.x Murphy JD, Gelfand HJ, Bicket MC, Ouanes JP, Kumar KK, Isaac GR, Wu CL. Analgesic efficacy of intravenous naloxone for the treatment of postoperative pruritus: a meta-analysis. J Opioid Manag 2011;7:321-7.10.5055/jom.2011.007321957831 Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine’s analgesic potency and attenuate opioid tolerance/dependence. Pain 2000;84:121-31.10.1016/S0304-3959(99)00223-710666516 Monitto CL, Kost-Byerly S, White E, Lee CK, Rudek MA, Thompson C, Yaster M. The optimal dose of prophylactic intravenous naloxone in ameliorating opioid-induced side effects in children receiving intravenous patient-controlled analgesia morphine for moderate to severe pain: a dose finding study. Anesth Analg 2011;113:834-42, http://dx.doi.org/10.1213/ANE.0b013e318229a4410.1213/ANE.0b013e31822c9a44 Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signalling. Neuroscience 2005;135:247-61.10.1016/j.neuroscience.2005.06.003 Breivik H, Werner MU. Combining an oral opioid-receptor agonist and the antagonist naloxone: a smart drug design that removes some but not all adverse effects of the opioid analgesic. Scand J Pain 2014;5:72-4.10.1016/j.sjpain.2014.02.004 Hesselbarth S, Hermanns K, Oepen P. Prolonged-release oxycodone/naloxone in opioid-naive patients - subgroup analysis of a prospective observational study. Expert Opin Pharmacother 2015;16:457-64, http://dx.doi.org/10.1517/14656566.2015.100173710.1517/14656566.2015.100173725612469 Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpenito J, Stambler N, Ramakrishna T. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopaedic surgery. J Hosp Med 2012;7:67-72, http://dx.doi.org/10.1002/jhm.9432199807610.1002/jhm.943 Michna E, Weil AJ, Duerden M, Schulman S, Wang W, Tzanis E, Zhang H, Yu D, Manley A, Randazzo B. Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis. Pain Med 2011;12:1223-30.2181016510.1111/j.1526-4637.2011.01189.x Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol 2014;7:345-58, http://dx.doi.org/10.2147/CEG.S5209725278772 Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United Eur Gastroenterol 2015, http://dx.doi.org/10.1177/2050640615604543(epub before print) Nordahl Christensen H, Olsson U, From J, Breivik H. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand J Pain 2016;11:104-10.2885044710.1016/j.sjpain.2015.12.007